Endolysin treatment against Staphylococcus aureus in adults with atopic dermatitis: A  randomized controlled trial

Staphylococcus aureus density is increased in many patients with atopic dermatitis (AD) and is thought to contribute to disease pathogenesis, interacting with an altered skin barrier and immunologic changes.1 S aureus might induce or aggravate inflammation through different mechanisms, for example through excretion of virulence factors, even if the S aureus overgrowth is primarily caused by other factors.2 Current guidelines only recommend antimicrobial therapy directed against S aureus in patients with clinically infected AD  based on a Cochrane review in which no clinical benefit of short-term antimicrobial treatment in patients with noninfected AD was found.

Source: Journal of Allergy and Clinical Immunology - May 26, 2019 Category: Allergy & Immunology Authors: Jill de Wit, Joan E.E. Tott é, Minke M.F. van Mierlo, Joyce van Veldhuizen, Martijn B.A. van Doorn, Frank H.J. Schuren, Sten P. Willemsen, Luba M. Pardo, Suzanne G.M.A. Pasmans Tags: Letter to the Editor Source Type: research